hp_logo_white v3

Heartwood Partners Portfolio Company Spotlight

Heartwood Partners is proud of its investment in Allentown, Inc. in partnership with second-generation CEO, John Cioro, and management.

Allentown, Inc. is a trusted and leading provider of high-quality vivarium laboratory equipment and related solutions.  Over the past 50 years, Allentown, Inc. has built long-standing relationships with preclinical researchers and renowned research institutions to enable the life sciences industry to discover breakthrough drugs and therapies that save lives and improve quality of life.

Allentown, Inc. has evolved from manufacturer to a key life sciences partner.  The company engineers tailored housing solutions that safeguard the efficacy and consistency of critical preclinical animal research results while, most importantly, improving research animal quality of life. 

“Our services to the biomedical research industry has always been rooted in integrity and care, and that is what has driven our growth and success,” stated John Coiro, CEO at Allentown, Inc.  “There is no limit to where Allentown can go or what Allentown can do.”

Click on the video below for an immersive experience highlighting Allentown, Inc.’s role in life-saving drug development.

Back to All

About Heartwood Partners

Heartwood Partners has been dedicated to investing in private companies for over 37 years, developing a well-established track record of supporting management teams to build and grow their companies, both organically and by add-on acquisition. You can learn more about Heartwood Partners at www.heartwoodpartners.com. We are currently investing from a $600 million committed fund, Heartwood Partners Private Equity Income Fund III, LP. In addition, we have access to additional equity capital through co-investment from our limited partners. Our approach is designed for a longer-term investment horizon (our average investment period has been 5-7 years) and to capitalize portfolio businesses conservatively using significantly more equity and less debt than is typical in private equity investments. We do this to strengthen portfolio company balance sheets, create significant operating and bank covenant flexibility and perpetuate a business’ ability to pay a cash yield out of excess cash flow to shareholders and management.